ACE-083

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H130203

CAS#: 81080-10-6

Description: ACE-083 is a follistatin-based therapeutic agent that acts locally and has been shown to increase muscle mass by binding myostatin and other muscle regulators. ACE-083 has undergone multiple clinical trials for various neuromuscular diseases, with varying results. ACE-083 has undergone phase 2 clinical trials for the treatment of FSHD, which found that although treatment with ACE-083 led to an increase in muscle volume, function did not improve, so the program of using ACE-083 for treating FSHD was discontinued.

Chemical Structure

img
ACE-083
CAS# 81080-10-6
Instruction

Theoretical Analysis

Hodoodo Cat#: H130203
Name: ACE-083
CAS#: 81080-10-6
Chemical Formula: C20H31N3O2
Exact Mass: 345.24
Molecular Weight: 345.490
Elemental Analysis: C, 69.53; H, 9.04; N, 12.16; O, 9.26

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ACE-083; ACE083; ACE 083

IUPAC/Chemical Name: N-(4-hydroxy-3,5-bis(piperidin-1-ylmethyl)phenyl)acetamide

InChi Key: AVPLCNNLKMYJHF-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H31N3O2/c1-16(24)21-19-12-17(14-22-8-4-2-5-9-22)20(25)18(13-19)15-23-10-6-3-7-11-23/h12-13,25H,2-11,14-15H2,1H3,(H,21,24)

SMILES Code: CC(NC1=CC(CN2CCCCC2)=C(O)C(CN3CCCCC3)=C1)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 345.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. https://n.neurology.org/content/98/23/e2356

2. Statland JM, Campbell C, Desai U, Karam C, Díaz-Manera J, Guptill JT, Korngut L, Genge A, Tawil RN, Elman L, Joyce NC, Wagner KR, Manousakis G, Amato AA, Butterfield RJ, Shieh PB, Wicklund M, Gamez J, Bodkin C, Pestronk A, Weihl CC, Vilchez-Padilla JJ, Johnson NE, Mathews KD, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022 Jul;66(1):50-62. doi: 10.1002/mus.27558. Epub 2022 May 9. PMID: 35428982; PMCID: PMC9321022.

3. Thomas FP, Brannagan TH 3rd, Butterfield RJ, Desai U, Habib AA, Herrmann DN, Eichinger KJ, Johnson-Cl NE, Karam C, Pestronk A, Quinn C, Shy ME, Statland JM, Subramony SH, Walk D, Stevens-Favorite K, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology. 2022 May 11;98(23):e2356–67. doi: 10.1212/WNL.0000000000200325. Epub ahead of print. PMID: 35545446; PMCID: PMC9202530.

4. Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018 Jun;57(6):921-926. doi: 10.1002/mus.26113. Epub 2018 Mar 15. PMID: 29486514; PMCID: PMC5969095.

5. Pearsall RS, Davies MV, Cannell M, Li J, Widrick J, Mulivor AW, Wallner S, Troy ME, Spaits M, Liharska K, Sako D, Castonguay R, Keates S, Grinberg AV, Suragani RNVS, Kumar R. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019 Aug 6;9(1):11392. doi: 10.1038/s41598-019-47818-w. PMID: 31388039; PMCID: PMC6684588.

6. Cao W, Zhang R. [Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020 May 10;37(5):578-583. Chinese. doi: 10.3760/cma.j.issn.1003-9406.2020.05.021. PMID: 32335891.